Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination

Cancer Letters

Volumn 200, Issue 2, 2003, Pages 97-105

  Hunter, Kent W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Gene expression; Genetic background; Genetics; Inefficiency; Metastasis; Microarray; Modifier; Mouse models; Progression; Quantitative traits

Indexed keywords

CANCER GENETICS; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CELL SUBPOPULATION; DNA MICROARRAY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; METASTASIS; MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL; TUMOR VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; GENETICS; MOUSE; REVIEW;

ANIMALS; HUMANS; LOSS OF HETEROZYGOSITY; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS;

EID: 0642335059     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00420-8     Document Type: Review

References (56)

1. Liotta L.A., Stetler-Stevenson W.G. Principles of molecular cell biology of cancer: cancer metastasis. DeVita S.H.V., Rosenberg S.A. Cancer: Principles and Practice of Oncology. fourth ed. 1993;134-149 Lippincott Co, Philadelphia.
2. Eccles S.A., Box G., Court W., Sandle J., Dean C.J. Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophys. 25:1994;279-291.
3. Heimann R., Lan F., McBride R., Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 60:2000;298-304.
4. Heimann R., Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J. Clin. Oncol. 18:2000;591-599.
5. Butler T.P., Gullino P.M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 35:1975;512-516.
6. Tarin D., Price J.E., Kettlewell M.G., Souter R.G., Vass A.C., Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 44:1984;3584-3592.
7. Glaves D., Huben R.P., Weiss L. Haematogenous dissemination of cells from human renal adenocarcinomas. Br. J. Cancer. 57:1988;32-35.
8. Weiss L., Nannmark U., Johansson B.R., Bagge U. Lethal deformation of cancer cells in the microcirculation: a potential rate regulator of hematogenous metastasis. Int. J. Cancer. 50:1992;103-107.
9. Holmgren L. Antiangiogenis restricted tumor dormancy. Cancer Metastasis Rev. 15:1996;241-245.
10. Luzzi K.J., MacDonald I.C., Schmidt E.E., Kerkvliet N., Morris V.L., Chambers A.F., Groom A.C. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153:1998;865-873.
11. Naumov G.N., MacDonald I.C., Weinmeister P.M., Kerkvliet N., Nadkarni K.V., Wilson S.M., Morris V.L., Groom A.C., Chambers A.F. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62:2002;2162-2168.
12. Riethmuller G., Klein C.A. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin. Cancer Biol. 11:2001;307-311.
13. Wong C.W., Lee A., Shientag L., Yu J., Dong Y., Kao G., Al-Mehdi A.B., Bernhard E.J., Muschel R.J. Apoptosis: an early event in metastatic inefficiency. Cancer Res. 61:2001;333-338.
14. Hunter K.W., Cozma D. The mouse in cancer research; past present and future(?). Curr. Genomics. 2:2001;1-26.
15. Muschel R.J., Williams J.E., Lowy D.R., Liotta L.A. Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am. J. Pathol. 121:1985;1-8.
16. Tuck A.B., Wilson S.M., Chambers A.F. Ras transfection and expression does not induce progression from tumorigenicity to metastatic ability in mouse LTA cells. Clin. Exp. Metastasis. 8:1990;417-431.
17. Guy C.T., Cardiff R.D., Muller W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. MCB. 12:1992;954-961.
18. Atchley W.R., Fitch W.M. Gene trees and the origins of inbred strains of mice. Science. 254:1991;554-558.
19. Beck J.A., Lloyd S., Hafezparast M., Lennon-Pierce M., Eppig J.T., Festing M.F., Fisher E.M. Genealogies of mouse inbred strains. Nat. Genet. 24:2000;23-25.
20. Lifsted T., Le Voyer T., Williams M., Muller W., Klein-Szanto A., Buetow K.H., Hunter K.W. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int. J. Cancer. 77:1998;640-644.
21. Bernards R., Weinberg R.A. A progression puzzle. Nature. 418:2002;823.
22. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:2003;49-54.
23. Hunter K.W., Broman K.W., Voyer T.L., Lukes L., Cozma D., Debies M.T., Rouse J., Welch D.R. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res. 61:2001;8866-8872.
24. Park Y.G., Clifford R., Buetow K.H., Hunter K.W. Multiple cross and inbred strain haplotype mapping of complex-trait candidate genes. Genome Res. 13:2003;118-121.
25. Wiltshire T., Pletcher M.T., Batalov S., Barnes S.W., Tarantino L.M., Cooke M.P., et al. Genome-wide single-nucleotide polymorphism analysis defines haplotype patterns in mouse. Proc. Natl. Acad. Sci. USA. 100:2003;3380-3385.
26. Wade C.M., Kulbokas E.J. 3rd, Kirby A.W., Zody M.C., Mullikin J.C., Lander E.S., Lindblad-Toh K., Daly M.J. The mosaic structure of variation in the laboratory mouse genome. Nature. 420:2002;574-578.
27. Weiss L. Metastatic inefficiency. Advances in Cancer Research. 54:1990;159-211.
28. Nowell P.C. The clonal evolution of tumor cell populations. Science. 194:1976;23-28.
29. Fidler I.J., Kripke M.L. Metastasis results from pre-existing variant cells within a malignant tumor. Science. 197:1977;893-895.
30. Kauffman E.C., Robinson V.L., Stadler W.M., Sokoloff M.H., Rinker-Schaeffer C.W. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 169:2003;1122-1133.
31. Steeg P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer. 3:2003;55-63.
32. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
33. Ruiter D.J., van Krieken J.H., van Muijen G.N., de Waal R.M. Tumour metastasis: is tissue an issue? Lancet Oncol. 2:2001;109-112.
34. Trainer D.L., Kline T., Hensler G., Greig R., Poste G. Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine. Clin. Exp. Metastasis. 6:1988;185-200.
35. Ishikawa M., Okada F., Hamada J., Hosokawa M., Kobayashi H. Changes in the tumorigenic and metastatic properties of tumor cells treated with quercetin or 5-azacytidine. Int. J. Cancer. 39:1987;338-342.
36. Kerbel R.S., Frost P., Liteplo R., Carlow D.A., Elliott B.E. Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J. Cell Physiol. Suppl 3:1984;87-97.
37. Olsson L., Forchhammer J. Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine, and characterization of an antigen associated with metastatic activity. Proc. Natl. Acad. Sci. USA. 81:1984;3389-3393.
38. Stopper H., Pechan R., Schiffmann D. 5-Azacytidine induces micronuclei in and morphological transformation of Syrian hamster embryo fibroblasts in the absence of unscheduled DNA synthesis. Mutat. Res. 283:1992;21-28.
39. Frost P., Kerbel R.S., Hunt B., Man S., Pathak S. Selection of metastatic variants with identifiable karyotypic changes from a non-metastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. Cancer Res. 47:1987;2690-2695.
40. Ried T., Heselmeyer-Haddad K., Blegen H., Schrock E., Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer. 25:1999;195-204.
41. Fidler I.J. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother. Pharmacol. 43 Suppl:1999;S3-S10.
42. Nakayama T., Taback B., Turner R., Morton D.L., Hoon D.S. Molecular clonality of in-transit melanoma metastasis. Am. J. Pathol. 158:2001;1371-1378.
43. Chambers A.F., Wilson S. Use of NeoR B16F1 murine melanoma cells to assess clonality of experimental metastases in the immune-deficient chick embryo. Clin. Exp. Metastasis. 6:1988;171-182.
44. Cheung S.T., Chen X., Guan X.Y., Wong S.Y., Tai L.S., Ng I.O., So S., Fan S.T. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res. 62:2002;4711-4721.
45. Fidler I.J., Yano S., Zhang R.D., Fujimaki T., Bucana C.D. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 3:2002;53-57.
46. Talmadge J.E., Wolman S.R., Fidler I.J. Evidence for the clonal origin of spontaneous metastases. Science. 217:1982;361-363.
47. Fidler I.J., Talmadge J.E. Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res. 46:1986;5167-5171.
48. Fidler I.J. Critical determinants of metastasis. Semin. Cancer Biol. 12:2002;89-96.
49. Puduvalli V.K. Brain metastases: biology and the role of the brain microenvironment. Curr. Oncol. Rep. 3:2001;467-475.
50. Alessandro R., Kohn E.C. Signal transduction targets in invasion. Clin. Exp. Metastasis. 19:2002;265-273.
51. Schirrmacher V., Fogel M., Russmann E., Bosslet K., Altevogt P., Beck L. Antigenic variation in cancer metastasis: immune escape versus immune control. Cancer Metastasis Rev. 1:1982;241-274.
52. Eaves I.A., Wicker L.S., Ghandour G., Lyons P.A., Peterson L.B., Todd J.A., Glynne R.J. Combining mouse congenic strains and microarray gene expression analyses to study a complex trait: the NOD model of type 1 diabetes. Genome Res. 12:2002;232-243.
53. Schadt E.E., Monks S.A., Drake T.A., Lusis A.J., Che N., Colinayo V., et al. Genetics of gene expression surveyed in maize, mouse and man. Nature. 422:2003;297-302.
54. T.H. Qiu, G.V.R. Chandramouli, N.W. Alkharouf, K.W. Hunter, P. Long, E.T. Liu, Analysis of Gene Expression Profiles in MMTV-PyMT Transgenic Mice in Different Genomic Background, Manuscript in preparation, 2003.
55. Hunter K.W., Welch D.R., Liu E.T. Genetic background is an important determinant of metastatic potential. Nat. Genet. 34:2003;23-24.
56. Park Y.G., Lukes L., Yang H., Debies M.T., Samant R.S., Welch D.R., Lee M., Hunter K.W. Comparative sequence analysis in eight inbred strains of the metastasis modifier QTL candidate gene Brms1. Mamm. Genome. 13:2002;289-292.